Vogue's Guide to the Different Types of Sunscreen You Need This Summer
But how does one choose that perfect sunscreen that will make you remember this very important step in your routine? To figure that out, you'll have to understand what all of your options are. Below, the experts break down every type of sunscreen to help you make wise skin health (and shopping) decisions.
Types of Sunscreen
There are two types of sunscreens you can choose from: mineral sunscreens and chemical sunscreens. The difference between the two can be broken down as follows:
Mineral Sunscreens
Mineral sunscreens, also known as physical sunscreens, block the sun's harmful UV rays from penetrating the skin. As Marisa Garshick, MD, board-certified dermatologist at MDCS Dermatology, explains it, mineral sunscreens use zinc oxide and titanium dioxide to scatter and reflect the UV rays when it bounces off the skin to protect it from damage.
There are many pros of mineral sunscreen, but they are most known to be less irritating and great for sensitive skin. Though they may leave behind a white cast, Dr. Garshick says that newer formulations have been developed to minimize that. Options like the U Beauty's Multimodal Sheer Mineral Sunscreen or Shiseido's Ultimate Sun Protector Lotion Mineral SPF 60+ provide nourishing skincare benefits while also blending quite nicely into the skin.
Chemical Sunscreens
According to Hadley King, MD, a New York City-based board-certified dermatologist, chemical sunscreens absorb the sun's UV rays and create a chemical reaction to turn the UV rays into heat that will be released from the skin. They're usually made of chemical ingredients such as oxybenzone, octinoxate, avobenzone, octisalate, octocrylene, and homosalate, and Dr. Garshick says these formulations are generally easier to rub in and won't leave a white cast.
But because they are made of various chemical filters, she does warn that some people may experience some irritation or sensitivity to these types of formulas. But a lot of formulations are made with sensitive skin in mind, such as the EltaMD UV Clear Broad-Spectrum SPF 46 or the Medik8 Advanced Day Ultimate Protect SPF 50+. If you happen to like the feel of these chemical sunscreens more, you can easily opt for these gentle options over a mineral one.
Lotions, Sprays, Sticks, and More
Sunscreens also come in many forms. You can find a mineral and chemical sunscreen in a lotion, stick (the E.l.f. Cosmetics Suntouchable Invisi-Stick SPF 50 makes reapplying so easy while on the go), spray, and even serum format (cult-classic Australian sunscreen brand Ultra Violette is finally available in the U.S. and the Future Screen SPF 50 Facial Sunscreen Serum is a current fave among many). Mineral sunscreens also come in powder form like the classic Colorescience Sunforgettable Total Protection Brush-On Shield SPF 50. When it comes to choosing between these types of sunscreen, Dr. King says that you should pick the one most appropriate for your lifestyle.
What does SPF mean?
We're always told to look for sunscreen with SPF, but what does that actually mean? SPF stands for sun protection factor and as Dr. King explains it, it measures how much a sunscreen will shield your skin from ultraviolet B (UVB) rays, which can cause sunburn.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Wells Fargo Cuts Elevance (ELV) Price Target on Margin Uncertainty
Elevance Health, Inc. (NYSE:ELV) ranks among the . Wells Fargo kept its Overweight rating on Elevance Health, Inc. (NYSE:ELV) on July 15, but lowered its price target on the health insurer from $478 to $400. Wells Fargo applied a lower multiple of 10.5x to its 2026 earnings per share projection of $38.05, which is less than the previous multiple of 11.5x. designer491/ Wells Fargo stated that the primary driver of the reduced value multiple was uncertainty regarding margins in the Medicaid, Medicare Advantage (MA), and Health Insurance Exchange (HIX) segments for 2025. The firm also pointed out that there was 'relatively low visibility to improvement in 2026,' especially in the Medicaid and Health Insurance Exchange segments. However, it insisted that Elevance's valuation 'remains compelling once dust settles on estimates.' Elevance Health, Inc. (NYSE:ELV), previously Anthem, Inc., is a leading health-benefits provider in the United States. The company offers medical, pharmaceutical, dental, long-term care, disability, and behavioral health insurance under numerous brands, including Anthem Blue Cross, Blue Shield, Wellpoint, and Carelon. While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death
Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death originally appeared on Parade. Wrestling icon Hulk Hogan has died at the age of 71, following a reported cardiac arrest. The shocking news comes after Hogan opened up about his declining health and the toll his legendary wrestling career had taken on his body. Hulk Hogan Had 25 Surgeries in 10 Years In a September 2024 appearance on Logan Paul's 'IMPAULSIVE' podcast, Hogan revealed that he had undergone a staggering 25 surgeries over the past decade. 'I've had like 25 surgeries in the last ten years. Ten of them were back surgeries,' Hogan told Paul. 'Nobody told me this gimmick stuff was fake. I've had 10 back surgeries, both knees and both hips replaced, shoulders — everything.' The WWE Hall of Famer also reflected on the physically punishing early days of professional wrestling. He recalled how Andre the Giant once warned him about the dangerous condition of older wrestling rings. 'The equipment back in the day when I started wrestling in '77 was a little different than the rings and stuff you guys are working in now,' Hogan said. 'Andre used to tell me, 'Boss, don't fall down. You won't get back up.' It was like a 22-foot boxing ring that had lumps in it, boards sticking up—it was horrible.' Hulk Hogan's Health Issues Before His Death In the months leading up to his death, Hogan's public appearances sparked concern among fans. After appearing on Fox & Friends to promote his new wrestling league, many noted the WWE icon looked 'unwell.' Soon after, Hogan was reportedly hospitalized for neck and back issues, undergoing a minor cervical fusion surgery. Rumors quickly spread that he was on his 'deathbed,' but his representatives shut down those claims. 'He just needs from time to time a medical check-up,' a spokesperson reportedly told The Independent, adding there were 'no reasons to panic.' Hulk Hogan's Cause of Death: Cardiac Arrest Reported As of now, Hogan's cause of death is being reported as cardiac arrest, though official confirmation and more details are expected in the coming days. Hulk Hogan Underwent 25 Surgeries Before His Heartbreaking Death first appeared on Parade on Jul 24, 2025 This story was originally reported by Parade on Jul 24, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline
Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 18, Citi raised its price target of the stock to $22 from $15 while maintaining a 'Buy' rating. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. The price target hike comes as the company delivers top-line results from bezuclastinib (bezu) in non-advanced systemic mastocytosis (NonAdvSM). According to Citi, investors are increasingly viewing bezuclastinib as an improvement over Blueprint's Ayvakit. The research firm expects the company to deliver positive symptom and biomarker data at ASH in December. Beyond bezuclastinib, Cogent Biosciences is also advancing its other pipeline candidates. The company plans to release advanced systemic mastocytosis (AdvSM) data from the APEX trial in the second half of the year. It will also provide results from the PEAK trial for gastrointestinal stromal tumors (GIST). Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. It focuses on diseases caused by genetic mutations. Its lead program, bezuclastinib, is a tyrosine kinase inhibitor designed to target the KIT D816V mutation, which drives systemic mastocytosis, as well as other mutations in KIT exon 17. While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data